Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BIM-DRS Low Dose · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Bimatoprost-Drug Ring System Low Dose and Previously Implanted Commercially Available Monofocal IOL | EXPERIMENTAL | - |
| Bimatoprost-Drug Ring System High Dose and Previously Implanted Commercially Available Monofocal IOL | EXPERIMENTAL | - |
| Bimatoprost-Drug Ring System Low Dose with SpyGlass IOL (IOL with silicone pads (no drug)) | EXPERIMENTAL | - |
| Bimatoprost-Drug Ring System High Dose with SpyGlass IOL (IOL with silicone pads (no drug)) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BIM-DRS Low Dose | DRUG | Bimatoprost-Drug Ring System Low Dose |
| BIM-DRS High Dose | DRUG | Bimatoprost-Drug Ring System High Dose |
| SpyGlass IOL with silicone pads (no drug) | DEVICE | SpyGlass Intraocular Lens with silicone pads (no drug) |
Inclusion Criteria: * Diagnosis of mild to moderate open-angle glaucoma or ocular hypertension * Pseudophakic or planned removal of cataract * Female participants of childbearing potential must have a negative urine pregnancy test at the baseline visit and agree to the use of contraception Exclusi...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Timolol eye 0.5% |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Undisclosed |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol , 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test - Bimatoprost 0.01%, Reference - LUMIGAN |
| Alcon AG | ALC | 5 | N/A | Undisclosed |
| Sight Sciences, Inc. | SGHT | 3 | N/A | Undisclosed |
BIM-DRS Low Dose is an investigational small molecule being developed by SpyGlass Pharma, Inc. for the treatment of glaucoma and ocular hypertension. It is a bimatoprost drug ring system designed for use in pseudophakic patients diagnosed with open angle glaucoma or ocular hypertension. The drug is currently in Phase 1 clinical development.
BIM-DRS Low Dose contains bimatoprost, a prostaglandin analog that works by increasing the outflow of aqueous humor from the eye, thereby reducing intraocular pressure. It is delivered via a drug ring system placed in the eye. The drug is being studied for its safety, efficacy, and dose response in patients with glaucoma or ocular hypertension.
BIM-DRS Low Dose is developed by SpyGlass Pharma, Inc., a company traded under the ticker SGP. The drug is an investigational small molecule in the ophthalmology therapeutic area, currently in Phase 1 clinical trials for the treatment of glaucoma and ocular hypertension.
BIM-DRS Low Dose is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is designed to evaluate the safety, efficacy, and dose response of the bimatoprost drug ring system in patients with open angle glaucoma or ocular hypertension.
BIM-DRS Low Dose is being studied in one active Phase 1 clinical trial with the identifier NCT07641296. The trial, titled 'Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular Hypertension,' is not yet recruiting and plans to enroll 24 participants aged 22 years and older.